PTGX Q1 2020 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+133.8% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$20M-540.1% margin

Net Income

-$20M-550.6% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

+34.1%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$135M

Total Liabilities

$72M

Stockholders' Equity

$63M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$2M	+133.8%
Gross Profit	$4M	$2M	+133.8%
Operating Income	-$20M	-$15M	-34.5%
Net Income	-$20M	-$14M	-42.4%

Revenue Segments

License And Collaborative Revenue

$114M100%